Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
CC transcript
Appointed director
Inv. presentation
|
|
Altimmune, Inc. (PIP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/27/2023 |
8-K
| Appointed a new director |
| 05/12/2020 |
8-K
| Appointed a new director |
| 11/27/2018 |
8-K
| Appointed a new director|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 27, 2018 ALTIMMUNE, INC. Delaware 001-32587 20-2726770 910 Clopper Road, Suite 201S Gaithersburg, Maryland 20878 Registrant's telephone number including area code: 654-1450 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement ...",
"Employment Agreement, by and between Dr. Vipin K. Garg and Altimmune, Inc",
"Altimmune Appoints Vipin K. Garg, Ph.D. as its New President and Chief Executive Officer" |
|
| 01/19/2017 |
8-K
| Acquisition/merger/asset purchase announced, Appointed a new director|
Docs:
|
"Agreement and Plan of Merger and Reorganization, by and among PharmAthene, Inc., Mustang Merger Sub, Inc., Mustang Merger Sub LLC, Altimmune, Inc. and Shareholder Representative Services LLC, as representative of Altimmune Securityholders",
"Form of PharmAthene Voting Agreement",
"Form of PharmAthene Lock-Up Agreement",
"Form of Altimmune Lock-Up Agreement",
"Phillip MacNeill Retention and Severance Agreement",
"PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases Annapolis, MD and Gaithersburg, MD, January 19, 2017 -- PharmAthene, Inc. and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, announced today the signing of a definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction. Altimmune’ s current investors include Novartis Venture Fund, HealthCap, Truffle Capital and Redmont Capital. The combined company will be a fully-integrated and diversified immunotherapeutics company with four clinical stage and one preclinical stage programs. The proposed transaction does not affect PharmAthene’ s previously announced special one-time cash dividend of $2.91 per share of co..." |
|
| 05/21/2010 |
8-K
| Form 8-K - Current report |
|
|